Business Wire10.04.17
DexCom Inc., developer of continuous glucose monitoring (CGM) technology, has announced the availability of a public API, empowering third-party developers to connect patient-authorized CGM data into a broad range of software applications. This approach to CGM data sharing is intended to enable a rich ecosystem of novel solutions and put the user in control of where and how they interact with their glucose data.
“In launching this developer platform, Dexcom combines our CGM data expertise with the creativity of the developer ecosystem to enable new solutions and business models in the treatment and management of diabetes,” said Annika Jimenez, senior vice president of Data at Dexcom. “Dexcom believes in data mobility and customer choice. It also believes that the API opens up opportunities to drive Dexcom CGM data into the heart of new digital solutions for payers, providers, and most importantly people with diabetes.”
Continuous glucose monitoring allows people with diabetes to continuously track their blood glucose levels in real-time. Dexcom CGM systems provide dynamic glucose information every five minutes, which creates a continuous stream of glucose data that can be invaluable for individual and population diabetes management. The Dexcom API allows Dexcom to ensure CGM data collaboration is secure, patient-privacy-centric, and U.S. Food and Drug Administration-compliant, while supporting a broad variety of new solutions and business models.
"Diabetes is a data-driven disease," said Jeff Dachis, founder and CEO of One Drop, a digital diabetes management solution and Dexcom API user. “By combining Dexcom data with One Drop’s ability to connect users, coaches and diabetes peers, this partnership will help drive innovation and will bring about more affordable, accessible, scalable, and effective solutions. It's a big win for people with diabetes.”
As of today, developers in the United States can register and immediately access the Dexcom API. Several companies and startups in the diabetes space including One Drop, Nutrino, Tidepool, Rimidi, Evidation, Ensa, and App Practice are already accessing the API for patient-approved CGM data retrieval.
“AppPractice’s new platform allows clinicians to view their patient’s glucose on the same day via their smartphones, as part of their mHealth patient care practice,” said Dr. Rakesh Patel, endocrinologist, entrepreneur and founder of App Practice. “By using the data from the Dexcom API, our clinicians can now make timely changes and adjust insulin for their patients more effectively. Access to patient data like this enables clinicians to dramatically improve patient care and can lower healthcare costs.”
Dexcom customers will benefit from the apps these companies have developed in many ways; for example:
“Dexcom has always been a pioneer in diabetes technology,” said Kevin Sayer, president and CEO of Dexcom. “Now we are extending our thought leadership into the data our device generates by enabling broad collaboration with digital health partners.”
DexCom Inc., headquartered in San Diego, Calif., develops and markets continuous glucose monitoring (CGM) products and tools for adult and pediatric diabetic patients.
“In launching this developer platform, Dexcom combines our CGM data expertise with the creativity of the developer ecosystem to enable new solutions and business models in the treatment and management of diabetes,” said Annika Jimenez, senior vice president of Data at Dexcom. “Dexcom believes in data mobility and customer choice. It also believes that the API opens up opportunities to drive Dexcom CGM data into the heart of new digital solutions for payers, providers, and most importantly people with diabetes.”
Continuous glucose monitoring allows people with diabetes to continuously track their blood glucose levels in real-time. Dexcom CGM systems provide dynamic glucose information every five minutes, which creates a continuous stream of glucose data that can be invaluable for individual and population diabetes management. The Dexcom API allows Dexcom to ensure CGM data collaboration is secure, patient-privacy-centric, and U.S. Food and Drug Administration-compliant, while supporting a broad variety of new solutions and business models.
"Diabetes is a data-driven disease," said Jeff Dachis, founder and CEO of One Drop, a digital diabetes management solution and Dexcom API user. “By combining Dexcom data with One Drop’s ability to connect users, coaches and diabetes peers, this partnership will help drive innovation and will bring about more affordable, accessible, scalable, and effective solutions. It's a big win for people with diabetes.”
As of today, developers in the United States can register and immediately access the Dexcom API. Several companies and startups in the diabetes space including One Drop, Nutrino, Tidepool, Rimidi, Evidation, Ensa, and App Practice are already accessing the API for patient-approved CGM data retrieval.
“AppPractice’s new platform allows clinicians to view their patient’s glucose on the same day via their smartphones, as part of their mHealth patient care practice,” said Dr. Rakesh Patel, endocrinologist, entrepreneur and founder of App Practice. “By using the data from the Dexcom API, our clinicians can now make timely changes and adjust insulin for their patients more effectively. Access to patient data like this enables clinicians to dramatically improve patient care and can lower healthcare costs.”
Dexcom customers will benefit from the apps these companies have developed in many ways; for example:
- Clinicians can now view their diabetes patients’ glucose data on their smartphones, as part of their mobile practice patient care and billing workflows.
- Patients are able to receive automated, personalized insights gained from combining data from their diabetes devices, medical records, and other apps and wearables.
- Dexcom users can explore how their food choices impact their glucose control and connect with and learn from coaches and diabetes peers in a data-driven community.
“Dexcom has always been a pioneer in diabetes technology,” said Kevin Sayer, president and CEO of Dexcom. “Now we are extending our thought leadership into the data our device generates by enabling broad collaboration with digital health partners.”
DexCom Inc., headquartered in San Diego, Calif., develops and markets continuous glucose monitoring (CGM) products and tools for adult and pediatric diabetic patients.